Benzoylurea derivatives as a novel class of antimitotic agents: Synthesis, anticancer activity, and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3094-3103

  Song, Dan Qing ^a   Wang, Yan ^a   Wu, Lian Zong ^a   Yang, Peng ^a   Wang, Yue Ming ^a   Gao, Li Mei ^a   Li, Yan ^b   Qu, Jing Rong ^b   Wang, Yong Hong ^a   Li, Ying Hong ^a   Du, Na Na ^a   Han, Yan Xing ^a   Zhang, Zhi Ping ^a   Jiang, Jian Dong ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORO 3 (BROMOACETAMIDO)BENZOYLUREA; 6 FLUORO 3 (IODOACETAMIDO)BENZOYLUREA; ANTIMITOTIC AGENT; PROTEIN BCL 2; UREA DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; DAUDI CELL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATOMA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MELANOMA CELL; MICROTUBULE ASSEMBLY; PANCREAS CANCER; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ACETANILIDES; ANIMALS; ANTIMITOTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; UREA;

EID: 44949138221     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070890u     Document Type: Article

References (33)

1. (a) Jordan, M. A.; Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 1998, 10, 123-130.
2. (b) Kiselyov, A.; Konstantin, V. B.; Sergey, E. T.; Nikolay, S.; Alexandre, V. I. Recent progress in discovery and development of antimitotic agents. Anti-Cancer Agents Med. Chem. 2007, 7, 189-208.
3. (c) Jeffrey, R. J.; Denis, R. P.; Mohammed, M. D.; Pearl, S. H. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 2007, 7, 107-117.
4. (a) Giannakakou, P.; Sackett, D.; Fojo, T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J. Natl. Cancer Inst. 2000, 92, 182-183.
5. (b) Supana, S.; Sannu, A. T. Drug target interaction of tubulin-binding drugs in cancer therapy. Expert Rev. Anticancer Ther. 2006, 6, 1433-1447.
6. Pettit, G. R.; Cragg, G. M.; Singh, S. B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 1987, 50, 386-391.
7. (a) Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. 2004, 4, 253-265.
8. (b) Wilson, L.; Jordan, M. A. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J. Chemother. 2004, 16, 83-85.
9. Islam, M. N.; Iskander, M. N. Microtubulin binding sites as target for developing anticancer agents. Mini-Rev. Med. Chem. 2004, 4, 1077-1104.
10. (a) Freilich, R. J.; Balmaceda, C.; Seidman, A. D.; Rubin, M.; DeAngelis, L. M. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996, 47, 115-118.
11. (b) Hilkens, P. H.; Verweij, J.; Vecht, C. J.; Stoter, G.; van den Bent, M. J. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 1997, 8, 187-190.
12. (a) Fojo, A. T.; Menefee, M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin. Oncol. 2005, 32, S3-S8.
13. (b) Dumontet, C.; Sikic, B. I. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport and cell death. J. Clin. Oncol. 1999, 17, 1061-1070.
14. (a) Islam, M. N.; Iskander, M. N. Microtubulin binding sites as target for developing anticancer agents. Mini-Rev. Med. Chem. 2004, 4, 1077-1104.
15. (b) Chern, J. W.; Leu, Y. L.; Wang, S. S.; Jou, R.; Lee, C. F.; Tsou, P. C.; Hsu, S. C.; Liaw, Y. C.; Lin, H. M. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents. J. Med. Chem. 1997, 40, 2276-2286.
16. (a) Ling, Y. H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P. J.; Adama, J.; Jiang, J. D.; Muggia, F. M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 2002, 1, 841-849.
17. (b) Ling, Y. H.; Liebes, L.; Jiang, J. D.; Holland, J. F.; Elliott, P. J.; Adama, J.; Muggia, F. M.; Perez-Soler, R. Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 2003, 9, 1145-1154.
18. Jiang, J. D.; Roboz, J.; Imre, W.; Deng, L.; Ma, L. H.; Holland, J. F.; Bekesi, J. G. Synthesis, cancericidal and antimicrotubule activities of 3-(haloacetamido)-benzoylureas. Anti-Cancer Drug Des. 1998, 13, 735-747.
19. (a) Jiang, J. D.; Davis, A. S.; Middleton, K.; Ling, Y. H.; Roman, P. S.; Holland, J. F.; Bekesi, J. G. 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res. 1998, 58, 5389-5395.
20. (b) Jiang, J. D.; Denner, L.; Ling, Y. H.; Li, J. N.; Davis, A.; Wang, Y.; Li, Y.; Roboz, J. L.; Wang, L. G.; Roman, P. S.; Marcelli, M.; Bekesi, G.; Holland, J. F. Double blockade of cell cycle at G1-S transition and M phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand. Cancer Res. 2002, 52, 6080-6088.
21. Jiang, J. D.; Wang, Y.; Roboz, J.; Strauchen, J.; Holland, J. F.; Bekesi, J. G. Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound. Cancer Res. 1998, 58, 2126-2133.
22. Li, J. N.; Song, D. Q.; Lin, Y. H.; Hu, Q. Y.; Yin, L.; Bekesi, G.; Holland, J. F.; Jiang, J. D. Inhibition of microtubule polymerization by 3-bromopropionylamino benzoylurea (JIMB01), a new cancericidal tubulin ligand. Biochem. Pharmacol. 2003, 65, 1691-1699.
23. Hwang, K. J.; Park, K. H.; Lee, C. O.; Kim, B. T. Novel benzoylurea derivatives as potential antitumor agents; synthesis, activities and structure-activity relationships. Arch. Pharmacal Res. 2002, 25, 781-785.
24. Okada, H.; Koyanagi, T.; Yamada, N.; Haga, T. Synthesis and antitumor activities of novel benzoylphenylurea derivatives. Chem. Pharm. Bull. 1991, 39, 2308-2315.
25. (a) Okada, H.; Koyanagi, T.; Yamada, N. Synthesis and antitumor activities of prodrugs of benzoylphenylureas. Chem. Pharm. Bull. 1994, 42, 57-61.
26. (b) Okada, H.; Kato, M.; Koyanagi, T.; Mizuno, K. Synthesis and antitumor activities of water-soluble benzoylphenylureas. Chem. Pharm. Bull. 1999, 47, 430-433.
27. Inaba, T.; Tanaka, K.; Takeno, R.; Nagaki, H.; Yoshida, C.; Takano, S. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones, antiarthritic effect of 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem. Pharm. Bull. 2000, 48, 131-139.
28. Baker, B.; Devan, B. P. Sequence-specific cleavage of DNA by N-bromoacetyldistamycin. Product and kinetic analysis. J. Am. Chem. Soc. 1989, 111, 2700-2712.
29. (a) Luduena, R. F.; Roach, M. C. Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol. Ther. 1991, 49, 133-152.
30. (b) Legault, J.; Gaulin, J. F.; Mounetou, E.; Bolduc, S.; Lacroix, J.; Poyet, P.; Gaudrealt, R. Microtubule disruption induced in vivo by 1-aryl-3-(2-chloroethyl)urea, a novel class of soft alkylating agents. Cancer Res. 2000, 60, 985-992.
31. Hargreaves, A. J.; Glazier, A. P.; Fiaskos, J.; Mullins, F. H.; Mclean, W. G. The disruption of brain microtubules in vitro by the phospholipase inhibitor p-boromophenacyl bromide. Biochem. Pharmacol. 1994, 47, 1137-1143.
32. Dolan, M. E.; Fleig, M. J.; Feuerstein, B. G.; Basu, H. S.; Luk, G. D.; Casero, R. A.; Marton, L. J. Effect of 1,19-bis(ethylamino)-5,10,15- triazanonadecane on human tumor xenografts. Cancer Res. 1994, 54, 4698-4702.
33. Yagi, M. J.; Bekesi, J. G. Evaluation of p-F-Phe-m-bis-(2- chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia. Cancer Chemother. Pharmacol. 1990, 26, 215-220.